David Schneider, MD
Cardiovascular Disease · Burlington, VTNPI 1285737429
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,900 of the $6,940 with a category attached, or 99.4%. Chiesi USA, Inc. accounts for 99.4% of it on its own, with 1 other manufacturer making up the rest.
Across 3 payments — averaging $2313.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Chiesi USA, Inc.$7K
- Janssen Research & Development, LLC$40
Across 51 payments — averaging $1985.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$48K
- CSL Behring$30K
- Lexicon Pharmaceuticals, Inc.$9K
- Amryt Pharma Holdings Ltd$8K
- E.r. Squibb & Sons, L.L.C.$4K
- Aegerion Pharmaceuticals, Inc.$2K
What the payments were for
- Consulting fees$6,90099%
- Food & beverage$401%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Chiesi USA, Inc. | 2 | $6,900 |
| Janssen Research & Development, LLC | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KENGREAL$6,900
How this compares
$6,940 in reported general payments places this provider in the 70th percentile of 27 cardiovascular disease providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 64 | $94,570 |
| Repatha SureclickEvolocumab | 55 | $64,217 |
| Praluent PenAlirocumab | 29 | $24,467 |
| Ezetimibe | 102 | $5,858 |
| Dofetilide | 14 | $4,768 |
| Candesartan Cilexetil | 29 | $2,329 |
| Rosuvastatin Calcium | 109 | $2,192 |
| Metoprolol Succinate | 72 | $1,501 |
| Carvedilol | 103 | $1,403 |
| Atorvastatin Calcium | 99 | $1,308 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 27 | $1,071 |
| Lisinopril | 100 | $1,058 |
| Torsemide | 37 | $866 |
| Valsartan | 30 | $774 |
| Amlodipine Besylate | 71 | $543 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Burlington
- Harold DauermanBurlington$248K
- Daniel LustgartenBurlington$171K
- Shubash AdhikariBurlington$59K
- Adipong BrickshawanaBurlington$37K
- Thomas GillilandBurlington$35K
- Benjamin IrvineBurlington$11K
- Ahmed HarhashBurlington$6K
- Sharan SharmaBurlington$4K
- Trace BarrettBurlington$4K
- Sherrie KhadangaBurlington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.